BioTime Subsidiary Asterias Biotherapeutics Reports the Successful End-of-Phase II FDA Meeting for Immunotherapy in Acute Myeloid Leukemia
Provides Direction for Late-Stage Development of AST-VAC1 in Acute Myeloid Leukemia
ALAMEDA, Calif.–(BUSINESS WIRE)–Feb. 24, 2016– BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its subsidiary, Asterias Biotherapeutics (“Asterias”), has successfully completed an End-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) for AST-VAC1, its investigational therapy targeting acute myeloid leukemia (AML). [Read more…]